On the other hand, a recent meta-analysis of 16 randomized controlled trials in 7192 people with type 1 diabetes showed that the addition of SGLT-2 inhibitors reduced the glycated hemoglobin (HbA1c), fasting plasma glucose, mean amplitude of glucose excursions, and total insulin dosage, while not reducing the risk of hypoglycemia. Here, INS is linked to Hypoglycemia.